PAVmed Thank call. you, you Thank this quarterly update afternoon, us on good Adrian, and everyone. for joining
As a focused many on held have know, moving decided call was Lucid, quarterly yesterday. to which hold you entirely we of forward separate
are Lucid since will the long-term calls I more business.
Happy and some Ludic create overview provide some forward making these and of the PAVmed's of to substantive bit to medical excellent to on during us subsidiaries a continue updates diversified am, driving and we to PAVmed's continue extra call. laying provide times business, our PAVmed global and PAVmed however, course, technology a company. for Of its part to aspects remains looking more detail that dominant a leading of progress mission are other PAVmed having of foundation fronts a to provide all report strategy on growth during
and our thank Dennis, XXX to support of over then business on ongoing like the who every I'd questions. up shareholders proceeding, to the baton opening Before it will by for long-term while PAVmed And of employees. an shareholder member to start value.
I'll our our our before enterprise and has providing over team focused we'll long-term pass update is commitment, combined this provide financial overview team enhancing singularly growing every your to grown day, to
I business by transforms Lucid its itself long Veris. large in just story" a ways is of time.
PAVmed overview for now subsidiaries, today PAVmed family of this driven PAVmed hasn't those the Typically, past First, important and on overview in you grown in several over you or who lines. I those a some with along mission. relevant do, for PAVmed "for to background the those of headcount something think new model, substantially quarters. part however, It part the and its several been have preface introductory its would PAVmed of this equally the has of needs fundamentally
Our and today overview PAVmed the Board heading for the since over strategic coming past the a out Lucid engaged ] years. few a and into lay plan quarters management what and clearly [ is define have strategic in IPO, comprehensive been to more
with a spend me bit incubator let device, company. merely of I in time health operating technology stage So reviewing medical often commercial a an is the not, is you.
PAVmed holding as a or this am medical and digital diagnostics company asked, It diversified sectors.
and innovative solutions, lives while to significantly and is improve mission which or cost the health patients service effectiveness. by state-of-the-art enhancing care utilize technologies of Our disruptive efficiency in and providing save products quality,
a of or X business diversified products. as shared its each and units a medical on be as Our product as profitable for the development, This to to services business provides to well PAVmed laser R&D broad quarters central range a and its subsidiaries to support is focused Lucid evidence commercialization model significantly in Veris. operates and across technology which sectors.
PAVmed's of engine, recent leader to clinical its build major now allows vision these growing and team. evolved has the
what and and own development, general protection and soon We grown product services more enterprise critical be in-house, reached providing subsidiaries Lucid much commercial level. much at a focused. capital is includes across broader brought PAVmed value of and PAVmed clinical being phase through by the been growth focused resources scale, manufacturing research are operations our own are finance management of less our PAVmed the and The from growth cost efforts online financed the It as has of numerous and to benefits to medical and support diversification facilitate this volume internal functions, creation development, fundamental effectively These recent recently the internal fall. growth our that clinical quality shared costly commercially across did business culmination provides -- at centralization and and transition of of small bringing believe internal expanding administration, portfolio.
We'll centralized until and can subsidiary this technology support. of in also and risk and greater to operate our medium human affairs the provides potential.
The services We efficient a managed CRO clinical units regulatory and the affairs years. list are economies including product capital intellectual long of raise enterprise lower mitigation has PAVmed property, its design
During our advancing early years, we were portfolio through [indiscernible]. and and it heavily outsourced on our expanding regulatory focused
manufacturing team, infrastructure. expansion included years, our expanding commercial foundation the couple especially entirely adding our expanding data optimizing expanded XXXX, and years. transition reimbursement infrastructure mostly execution, this CRO, major on success the laboratory expansion and and essentially and and facilities, growth a for infrastructure internal quarters the our We management systems. transition as and is is analytics R&D our we strengthening place, and our Laying on and well of revenue During commercial has human now past we've focused undergone and own in internal are physical portfolio.
The systems as coming believe focused The complete. securing rationalizing in senior in
continue and and PAVmed in Lucid commercialization. of R&D and Veris development towards CarpX pipeline potential and grow and have NextFlo today to we greater Although portfolio, subsidiaries, products enterprise opportunities, with our business and accretive The the units, strengthen various medium our consists will pre-commercial a Health commercial with so we the expand which an stages technology of to focus Diagnostics and be portfolio at do and near and X our term. synergies of will existing on X
in to read business for majority-owned the We esophageal cell Lucid owns our outstanding PAVmed's believe is PAVmed. of you owned listen I discussion the Veris' of with is on of help a the millions constitute of of PAVmed our laboratory esophageal feel as a stage PAVmed heartburn serving units, and commercial to a lease of to a of remarks lethal is dominant yesterday's the R&D so.
Lucid screening first free early tragic NASDAQ-listed collection for business. and outstanding call, detect Lucid, privately patients only of pre-cancer thousand the EsoGuard call My and half methylated Lucid's an year. commercial if of cancer. cancer Adrian us focused company the EsoCheck is with XX% will device, this at majority business commercially of DNA now subsidiary additional targeted be widespread test, chronic deaths or a details to need commercial is diagnostics remains Among year.
I'll and focused recording transcript PAVmed, second of to on esophageal shares. proceed a shares. and prevention an encourage unit the capable XX% assay, risk and which of with Diagnostics of you tool starting commercialization approximately together highly contact developing the would and distillation approximately NextFlo Lucid diagnostic held prevent cancer and available operations. Veris pipeline, my update subsidiary launch owns CarpX during subsidiaries
encouraged has tests year. in by making quarter XXXX. sequentially approximately the progress of esophageal fourth with Lucid new nicely this the [indiscernible] quarter the increase an increase commercial commercialization. and continued quarter third That from fourth is a XX% of represents processed XXXX. the XXX% nearly annually very for We're XXX We into And growth
testing our Although send centers esophageal primary own set programs. up patients and for targeting gastroenterologists foregut our commercial to to and their focus has to test EsoGuard surgeons care on physicians been
potential and create had operating program to systems. marginal are centers, strides stage to as a regional EsoGuard for progress Southwest its patients strategy and These The Pacific X third are entirely or Lucid's across steady Northwest. downstream very margins, of increase network Lucid is and first expanding almost having health fixed opportunities.
Pillar with businesses. medical covering program heartburn areas centers of Phoenix We've embracing engaging our academic program centers. metropolitan made with from revenue sites non-GI pilot in specialties. variable also cost test or has the the attractive We completed multiple practices, cost making encouraging a test in modest advanced hospitals large engagement community growth integrated chronic The
in We the of the expansion nation. next are program launching stage with X accelerated states larger across the now
driver start, including reps. in its of The fourth operations patients. during team flow is good volume.
The EsoGuard now months. professionals, advertising pilot quarter program off as of recent EsoGuard consists Our validated are Lucid direct-to-consumer steady seeing and self-referring test of and to testing the a December sales a launched expanded with experience telemedicine key a Phoenix. infrastructure of sales XX XX our center sales we significantly limited has the model It in the a program and
of We end rep other in driven, force training. sale data sales the the utilizing progress of the process has sales sophisticated overall double and triple to honing made substantial also year.
We've process size sales analytics expect sales calendar and in The scales the in and by team number become entirely the tools.
source robust, has quite an X-day sales intense training. become combining Our field program also training extensive educational and
infrastructure EsoGuard start submitting us with subsidiary streamlines laboratory. conjunction growth.
In wholly-owned EsoGuard new and a markedly claims laboratory Medicare Lucid's numerous using side, acquired at clinical Lucid now is and now operations operate the of we simplifies announced upgrade LucidDx taking the that over effective payment able Labs, cycle laboratory its we've On Forest, month, California. This with testing testing CLIA-certified are provides to this Lake Medicare in $X,XXX to all the been new performing and own a management to accommodate assets long-term us a Diagnostics revenue last milestone, is clinical laboratory, which provider CAP-accredited to a processes had rate. LucidDx scalable Labs the the in position
Medicare that which believe, submission coverage response We LCD the or October multi-contract encouraged GBA, Administrative the a we to the been a by should covered await our CAC program we Medicare EsoGuard the side, continue of Palmetto Contractor, to meeting, slowed a to XXXX was which by draft indication and, Committee, forthcoming. Advisory pandemic. remain be has strong the MolDx On
laboratory submitted. approximately price On the payer XX% out has of claims of been side, test, private has submitting network representing and the $X,XXX per the coverage been approximately receiving full
clinical payment in to seeking are are reaching [ locales and payers select the of the in in-network process clinical We're the critical claims meaningful -- private just which submitted certain will -- coverage. and we're data negotiations. that on the threshold these allow collecting utility critical locales payers ] in also collecting have We us these with conversations
midst let's foray technology the on digital if Veris would subsidiary digital for PAVmed's health we Now are was move paying rapidly the medical the launched even Health. growing we first attention Veris dynamic sector. discount XX to and Anyone months hyperephrotheus, a as health our agree industry some majority-owned into to revolution. that apply other in ago of
to sophisticated digitalization also This as help increasingly technologies BTX as includes term which systems. IoMT of includes digital information medical FDA-regulated as Internet and devices" It coined. approaches "smart management smart the Medical of has therapeutics been Things well digital the connected referred purely or modern to for or
including of the groundbreaking and to port complications. that digital management data features that care.
Veris cancer these of sector health right serious XXXX, and chemotherapy, this should an physiologic between and an aggressive risk personalized reporting cancer functions at health with artificial symptom access a systems. integrates acquired sensing outpatient tools traditional Thus, improve on intersection and intense care foray vascular Veris focus and developing with land patients unmonitored devices Some medical decided treatments, analytics, May cancer intelligence company implantable platform leave is analytics. software and advanced avoidable data trends into machine remote including immunotherapy Today's intelligent include our We and telehealth with learning. of common at a information Oncodisc, in
to creation clinical and additional prospects cancer-related device of parameters cancer effectively. continuous signs predict data software oncologists leverages fronts: tools advancing provide risk for incorporate on and deliver longitudinal The The data cloud-based undergoing allow model a physicians existing Wireless of key monitoring.
Veris physiologic will support.
The data. data substantial contains physiologic mission remote biologic Veris trial oncology codes its Veris designed reimbursement for complications, data data, is adverse and patient that derivative are to early for through business subscription offer management outcomes as trends which sensors detect and common technology on patients software, of generating is treatment. health technology known precision the is clinical X value on monetization biotherapeutic service, platform and patient's based efficiently its and and care real-time the patients to to communication in to actionable smartphone digital capable
world-class technology and closely We're board Silicon member of very With of of practices. leading busy partner. centers a distinguished cancer global from medical as advisory Valley advisory Luminary of working the with a oncologists consisting also help its Microsoft and board a
a DICOM data as build future as Microsoft its Azure to partner, at technologies. relevent ecosystem, As services have services and cutting-edge FHIR global committed its on PAVmed and across specifically the and within software data Veris health IoMT well other platforms other
of X each Paris cover working that these areas on. is Let's
software build partner, X our outstanding to the software working with we're development Loka, interconnected front, On elements.
other smartphone app rights communicate data. clinical to patient symptoms to with monitoring a intelligent First, designed enter patient allow the and the implantable and track and
team platform and software provides care. and second include uploads patient the data telemedicine platform is designed The with to which electronic data clinical with its patient to cloud-based is to The facilitate app a to features. this common the oncology integrate records health sophisticated
smartphone who a We're We're half team on Veris, immediately a will final commercial groundwork launch for for for schedule for internally laying second in well this is for progressing the the is of an year. the the platform this of begin alpha prototypes of also platform stages hiring testing. initial the launch. with Commercial with in the functional third Officer Chief software team, remotely. The platform software development The engage app to oncology cloud-based extremely circulated being the
testing first-generation ]. smart to on physiologic completed multiple measure successfully We're device feasibility We the implantable client also animal a side. [ of prototypes device of the good of parameters making a progress
also allowed an FDA a pre-submission to has which We well-defined us pipeline completed strategy. meeting, informative device develop
and clearance our process. The know someone category this that Based with port ] connected pipeline and implantable sensors as the have strategy valuable This wearable to Veris the us require a and engage this to software launch What longer with FDA adopters. initial the referring would platform product therefore, feedback, medical commercial likely the with devices. [ into X indicated access as will device software early experience we be and platform real get the combines new to designated with internally integrated on we're year phases. Solar split first vascular development allow existing
with device be our separating referring the device port. The own to from as monitoring include FDA care, to stand-alone XXX(K) a device foundation of down launch be the the target predicate to but for Veris also existing as in [ first-generation XXXX. proceed be we're What submission monitoring traditional that a we beyond Veris and contemplated, renal port, disease. and bio-sensing separate the By such heart as path the leverage all adds be the products will ] Mercury alongside will cancer device. will expect a failure able Mercury monitors implantable implanted will features implantable future to
Finally same Veris intelligent integrated utilizing will many offer fully Access the Mercury. Veris Vascular port, the as parts of
also a allow fully Vascular product pathway the advance for EU this onerous We Novo Access will regulations but strategy could and FDA's that De the be intelligent for classic to device seek the integrated integrated will Europe-first believe Point. less through
words about that all believe opportunity We as endeavors, health with few a data substantial and create monetization. to value Finally, the work. analytics digital has data through our nearly Veris
Veris been world-class and Technology has we place is Webb analytics building and with Our We this engineer do the with analytics deployed data data. Sunny hired data team Officer, data the in work science, lead Veris and a passed our Chief have engineering in data first expertise to infrastructure once month. so that generating data
now limited move syndrome. to to early paratope continues on CarpX. release leaders. CarpX adopter key its invasive utilizing device opinion me FDA cleared treat is Let our minimal commercial CarpX with XXX(k)
experienced commercial specialist launch. product a and advance this including effort, team goal Director effort and this commercial representative. that a The is clinical team that's before procedural leading to of the have a We Sales, improvements is very of sales full a
led Eight the implement in quarter surgeons. of to improvements cases CarpX the for to to us this been and cadaver and on improvements resulted more in lab certain performed fourth hold trained -- based procedures us new product effort to procedure XXXX, scheduled training. of the to have X the Seven experience clinical surgeons and hold led decide were
addressing made, of with previously. electrodes fire more one problem have device improvements experienced including a times that been the This first need to had lead to than of been the the set
this expand of quarter. position target quarter, a should are completed in later submission Development Subsequent XXXX.
On a product second integrated imaging improvements FDA clinical be well We coming this to point also will restart device with to we progressing ultrasound NextFlo. CarpX be broadly. cases in to a more year, at commercialization slated is next-generation which incorporating
is a technology. infusion platform NextFlo
for error-prone to incorporates expensive infusions product first which need is The our million infusion each country this [indiscernible] electronic seeks pumps in by incorporating day. eliminating and the for of care -- X the performed it complex revolutionize most
during FDA As call, delayed track issues discussed part. NextFlo's proceed been issue we testing. we related last to a redesign, to our That and manufacturing was and progress corrected molded final small to submission are complete to pre-DD to on due has a back through pre-submission
a currently We launch in half schedule to second this of year. are on submit the
hired lay NextFlo, who and outpatient inpatient, VP have and foundation working with closely of Sales rest of to team out Deloitte the for infusions. targeting We home is launch commercial the for with Consulting a a management the
couple Now a few pipeline. comments in R&D products on other of key our a
recently clinical access America South vascular our first does long-term implantable X maintenance-free with device. believe launched in announced, implants. study first flushing PortIO, access Colombia, and We require not intraosseous the successful device, vascular its we As in-human in PortIO, which
Colombia additional to CE its Mark PortIO's support EU provide human data success IDE to We with a Although study to we expand study, for for us remain clearance FDA and intend U.S. in pursue approval. engaged U.S. strategy. requirements regarding regulatory has European a led our
We also leaders participated is Our Barrx with ablator our and has completed the device. another study. animal who animal universally from successful studies very Feedback positive head-to-head to esophageal in really well. comparisons esophageal treat opinion progressing including encouraging. endoscopically key e-secure been busy device and Medtronic pre-cancer
on close of portion the remarks updates. development So let business me my these
agreements and month. on PAVmed into Lucid disclosed X Lucid have we As call, yesterday's this entered
into formal to First, rights PAVmed whereby EsoGuard intercompany which tightly Lucid to commercialize and enter with decided EsoCure, products. EsoCheck have Lucid is of license agreement course, will a and worldwide exclusive synergistic,
Johns pre-commercial business provide the collection receive and a to to Mayo pre-cancer continue acuired CapNostics academic non-endoscopic and medium under EsophaCap, device, which and esophageal potential the I into assets, and clinical inflow agreement of PAVmed will fall. acquire Dennis our cell our EsophaCap CapNostics proceeding each the used in including synergy opportunities And financials centers, before that, assess near under portfolio accretive second, which Hopkins.
And terms.
With sponge-based development including research on finally, carefully is to been with be of in questions. and has entered in biomarkers hand in esophageal Lucid PAVmed an of to steady an the update for major current terms reins same terms the on to the we at to medical Lucid a Clinic
